Company Overview of Rimonyx Pharmaceuticals, Ltd.
Rimonyx Pharmaceuticals, Ltd. engages in the discovery and development of drugs targeted at glycosaminoglycan and protein interactions. Its RX-111, an orally delivered small molecule drug for inflammatory bowel disease, is slated to enter Phase I clinical trials in the second quarter of 2005. Rimonyx Pharmaceuticals was founded by Paul Gregor in 2002. The company is based in Ness-Ziona, Israel.
Kiryat Weizmann Science Park
Sapir Street 7
Founded in 2002
972 8 940 4593
972 8 940 0917
Key Executives for Rimonyx Pharmaceuticals, Ltd.
Similar Private Companies By Industry
|Novotyr Therapeutics Ltd.||Middle East/Africa|
|Iluten Ltd.||Middle East/Africa|
|Polyrizon Ltd.||Middle East/Africa|
|T.P. Technology Pharmaceuticals Ltd.||Middle East/Africa|
|Ora Bio Ltd.||Middle East/Africa|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Rimonyx Pharmaceuticals, Ltd., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.